MSF Challenges Pfizer Bid For India Prevenar Patent
This article was originally published in PharmAsia News
Médecins Sans Frontières has opposed an Indian patent application by Pfizer for its best-selling pneumococcal conjugate vaccine (PCV13), saying the product is not sufficiently novel. The move comes as the country faces strong US and EU pressure to ease its stiff patent law while at the same time needing to reduce its number of child deaths, the highest in the world.
Register for our free email digests: